SEC Form 4 · accession 0001209191-19-016040
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David T Howton
Officer — EVP, General Counsel
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 8:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | D | 3,825 | $0.00 | D | 15,746 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $145.48 | Mar 4, 2019 | A | 45,000 | A | — | Mar 4, 2029 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1Forfeiture of 3,825 shares of restricted stock due to performance goal not met.
- F225% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.